Purpose: Solid organ transplant recipients (SOTR) have a high risk for severe COVID-19
infection; hence it is necessary to find alternative treatment strategies to protect these …

To the Editor, In their recent article, Yang et al. 1 reported reduced COVID-19 severity after
sotrovimab infusion in solid-organ-transplant (SOT) recipients with SARS-CoV-2 infection …

We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

Abstract Background Organ transplant recipients (OTRs) are less protected from vaccination
than immunocompetent hosts. Additional vaccine doses have shown increased …

Background Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment
against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs) …

The SARS-CoV-2 B. 1.1. 529 variant (Omicron) has spread aggressively around the world
with rapid transmission in Canada identified within days of its classification as a variant of …

Background & Aims: Bamlanivimab is a monoclonal antibody for the treatment of mild to
moderate cases of Coronavirus disease 2019 (COVID-19). The aim of the current meta …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale
transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients …

Background Despite widespread implementation of vaccination against coronavirus disease
2019 (COVID-19), solid organ transplant recipients (SOTRs) can remain particularly …

Background & Aims: Monoclonal antibodies cazirivimab and imdevimab are used as a
combination drug in the treatment of severe acute respiratory syndrome coronavirus-2 …